Targeting tumour cells lacking p53 function is a major goal of p53 research. One approach is to use an E1B 55k-de®cient adenovirus to target the checkpoint defect in p53-mutant cells (Bischo et al., 1996) . Another approach aims to restore p53 activity to the missense mutant p53 protein commonly overexpressed in tumours (Abarzua et al., 1996) . A third approach is to reintroduce wild type p53 into tumour cells by gene therapy, since tumour cells are often more sensitive than normal cells to the eects of exogenous wild type p53 (Roth et al., 1996) , particularly following loss of retinoblastoma protein expression (Sandig et al., 1997) .
A fourth possibility is to target tumour cells using transcriptionally active p53 mutants with altered sequence speci®city. This could be done by placing a toxic gene under the control of the p53 speci®city mutant in a gene therapy vector. In the simplest case, the p53 mutant would be expressed from the endogenous p53 locus. Several tumour-derived mutants have been described which induce p21-mediated G1 arrest eciently but fail to induce apoptosis (Friedlander et al., 1996; Ludwig et al., 1996) , and these mutants could potentially be used to activate transcription of a toxic gene placed under the control of the p21 promoter. However, to avoid expression of the toxic gene in cells containing wild type p53 it would be better to use p53 mutants which recognise sites to which wild type p53 can not bind. Rare tumours containing such mutants expressed from the endogenous p53 locus could be targeted by viruses transducing only the reporter, but in most cases both the p53 mutant and the reporter would need to be supplied by the virus. In this manuscript we describe the selection of p53 mutants with altered speci®city which could be used for this purpose, and show that a cell line with such a mutant can in principle be targeted in this way.
The p53 consensus binding site contains four copies the sequence RRR CW, where R is a purine and W is A or T (el-Deiry et al., 1992; Funk et al., 1992) . Analysis of the p53-DNA crystal structure (Cho et al., 1994) , in vitro binding data (Thukral et al., 1995) and preliminary screens in yeast (RI, unpublished data) suggested that amino acids 120 and 277 are good targets for mutagenesis to alter the speci®city of DNA binding. p53 was mutagenised by gap repair in yeast using primers that mutated these residues, and mutants were selected that activate transcription from the sequence TTT CATG AAA. Since the potential complexity is large if an additional PCR mutation elsewhere in the p53 molecule is required, primers encoding only histidine, lysine, asparagine, glutamine, arginine and serine at codons 120 and 277 were used. These amino acids include all residues capable of forming side chain hydrogen bonds with DNA except threonine, tyrosine, cysteine (the normal amino acid at codon 277) and amino acids with negatively charged side chains. Since mutation of amino acid 121 to phenylalanine alters the sequence-speci®city (it prefers G over A in the second and third positions in the pentamer, Freeman et al., 1994) , and analysis of potential structures when T replaces a purine at the ®rst position of the consensus suggested that replacement of amino acid 121 by a smaller residue might avoid clashes with the peptide backbone, amino acid 121 was replaced with glycine in the 5'-mutagenesis primer. The mutants obtained all contain histidine at position 277, plus either asparagine (`NGH', seven plasmids), histidine (`HGH', ®ve plasmids) or serine (`SGH' four plasmids) at position 120. To exclude the presence of additional random mutations, fragments containing only the desired mutations were backcloned into the parental vector.
Plasmids encoding the mutants were tested for the ability to activate transcription from normal and mutant binding sites in yeast (Figure 1a ). This showed that the mutants fail to activate from a normal binding site (RGC, Kern et al., 1991) , but activate strongly from the site used in the screen (26TTT CATG AAA). As expected, wild type p53 shows the opposite phenotype. Thus the mutants show a genuine change in speci®city in vivo. The in vitro DNA binding speci®city of the mutants tested in bandshift assays also shows the expected change: binding to a TTT site but not a wild type site (26AGG CATG TCT; Figure 1b) .
To con®rm that the change in speci®city is not a yeast artefact, the 277H mutants were tested in transcription assays in mammalian cells. A luciferase reporter regulated by the minimal p53 binding site in the cyclin G promoter was used as a control for wild type p53 transactivation, and compared with the same vector carrying either two copies (data not shown) or four copies of the TTT site (Figure 1c ). This demonstrated that the mutants also show a change in speci®city in mammalian cells. However, unlike yeast, Details of the mutagenesis strategy and plasmid construction are available on request. b-galactosidase assays and bandshift assays were performed as described (Freeman et al., 1994) . To avoid variable latency, the p53 carboxy-terminus was truncated at amino acid 368 in the bandshift assays (Freeman et al., 1994) p53 specificity mutants J Gagnebin et al where only two copies of the binding site are required, to detect transactivation of the reporter in mammalian cells four copies of the TTT site are required. In the wild type structure (Figure 2a ), the side chain amino group of lysine 120 forms hydrogen bonds with the O6 and N7 of guanine in the second position in the consensus, and the thiol group in cysteine 277 forms a hydrogen bond with the N4 of cytosine in the third position in the consensus (note that the cysteine contacts the`opposite' strand). The critical change to allow activation from the TTT site is mutation of amino acid 277 to histidine. This mutation can be accommodated in a modelled structure (Figure 2b-d) where it forms hydrogen bonds with the N6 and N7 of adenine (i.e., opposite the thymine in the third position in the consensus). The change in speci®city thus depends on the fact that the side chain of cysteine is too short to form a hydrogen bond with adenine in the TTT site; and histidine is too big to be accommodated when cytosine is present in the prototypic site.
The mutations at amino acid 120 are apparently less critical, since three dierent substitutions were found (asparagine, histidine and serine). It is possible to make plausible hydrogen bonds between asparagine or histidine and the O4 of thymine in the second position in the consensus (Figure 2b and c) , but the side chain of serine is too short to contact the DNA unless it does so via a water molecule (Figure 2d ). Although the contribution of the codon 120 mutations to the change in speci®city is uncertain from the model, none of the 16 plasmids rescued from yeast contained the wild type amino acid, lysine, at amino acid 120.
The December 1996 release of the IARC database of p53 mutations in tumours and cell lines (Hainaut et al., 1997) does not include histidine mutations at codon 277, possibly because that would require two changes (TGT to CAT). The only mutants found are 277 serine, tyrosine, phenylalanine and glycine. The last two have side chains lacking potential hydrogen bond donors, which should reduce the anity of 277F and 277G protein for all sites irrespective of sequence. Serine mutants would not be expected to bind a TTT site because serine has a similar length side chain to cysteine. Tyrosine was not tested at position 277 in the mutagenesis screen for technical reasons. The ®nding that 277H mutants can bind a TTT site shows that bulky side chains can be accommodated in a TTT site. Since the ring hydroxyl group of tyrosine can potentially form a hydrogen bond with the N6 of adenine opposite the second position of the consensus, we tested whether a tumour-derived 277Y mutant showed a change in sequence speci®city similar to that of 277H mutants. The mutant was tested alone and in combination with 120H/121G mutations (`HGY'). In yeast, the HGY mutant was similar to the HGH mutant: it activated well from a 2 x TTT site, and failed to activate from a wild type site (Figure 3a ). The mutant with 277Y alone failed to activate from a 26TTT site but did activate from a 46TTT site; the speci®city change was con®rmed because it was more active on a TTT site than a wild type site. In vitro DNA binding was tested by bandshift assay (Figure 3b ). This con®rmed the change in speci®city for both 277Y alone and the HGY mutant, which bound a TTT site but not a wild type site. In contrast with the transcription assay, where the single mutant only activated from a 46TTT site, under the bandshift conditions all of the mutants bound a 26TTT site, indicating that the in vivo conditions are more stringent. These results show that 277Y is a true sequence speci®city mutant selected in a human tumour.
The 277Y mutant was ®rst identi®ed in a Ewing tumour (Kovar et al., 1993) and subsequently has been described in head and neck cancer, breast cancer, colon cancer and sarcomas (Hainaut et al., 1997) . Transcriptionally active p53 mutants in tumours are potential targets for highly speci®c treatments based on transactivation of a toxic gene delivered, for example, by adenoviral gene therapy. To test whether cells with an endogenous 277Y mutant can in principle be targeted in this way, a Ewing tumour cell line with an endogenous 277Y mutant was transfected with transcription reporters, and transactivation by endogenous p53 was examined (Figure 4) . Control cell lines contained either wild type p53 or a 273C p53 mutant. The 273C mutant failed to transactivate any reporter. The 46TTT reporter gave higher luciferase activity when transfected into the 277Y mutant cells than when transfected into the wild type cells (13-fold higher induction with 277Y), whereas the reverse was true of the cyclin G reporter (two-fold higher induction with wild type). To rule out the possibility that the dierences in activity were due to p53 latency in some of the cell lines, the eect of X-irradiation on activity was examined (Figure 4 ). This produced a modest activation of transcription when the reporter matched the p53 allele, but it did not correct the speci®city change. Thus the change of speci®city of the 277Y mutant seen in yeast can also be seen with p53 expressed from the endogenous p53 locus in human tumour cells, and expression of a foreign gene can be targeted to these cells by a mutant p53-speci®c promoter.
The mutants described here are true sequence speci®city mutants, since they bind better to TTT than wild type sites. Other groups have also described mutants with altered sequence speci®city in vitro (Thukral et al., 1995) or altered biological properties in vivo (Friedlander et al., 1996; Ludwig et al., 1996) . Thukral et al. (1995) Eects on sequence speci®city of mutation at these residues is reasonable since amino acids 120 and 277 contact bases in the major groove in the p53/DNA cocrystal structure (Cho et al., 1994) . To identify mutants with altered speci®city in vivo, we performed a mutagenesis screen in yeast with full length p53, and to reduce the chance that our p53 mutants would bind to wild type sites, we used as a target a sequence mutated at three of the ®ve sites in the basic consensus pentamer. In contrast with Thukral et al. (1995) , we simultaneously mutagenised both amino acids 120 and 277; and on the basis of preliminary experiments and analysis of the crystal structure we changed amino acid 121 to glycine. The fact that we called for multiple changes and in vivo activity may explain why we did not select any mutants with glutamine or arginine at amino acid 277. We did, however, obtain some clones with asparagine at position 120, although changes at this position appear less critical than the 277H mutation.
143A, 175P and 181L mutant p53 are tumourderived mutants which retain the ability to transactivate p21 reporters and induce growth arrest, but they do not transactivate bax (143A and 175P) and IGF-BP3 (143A, 175P and 181L) reporters or induce apoptosis (Friedlander et al., 1996; Ludwig et al., 1996) . Since none of these mutations aects DNA contact residues, the exact mechanism resulting in the change in activity is not clear. Mutations remote from the DNA binding surface may in¯uence the overall structure, and thereby alter the alignment of the DNA contact residues. Many p53 mutations presumably act in this way, since mutation at over 90% of the codons in the DNA binding domain have been observed in tumours, and mutations at a similar number of sites will inactivate p53 as a transcription factor in yeast (Flaman et al., 1994) . Sequence speci®city is de®ned by a ratio of dissociation constants for dierent sequences. Since wild type p53 binds p21 sites better than bax or IGF-BP3 sites, which contain fewer matches to the p53 consensus, the simplest explanation for the behaviour of the 143A, 175P and 181L mutants is that they have mildly reduced anity but normal sequence speci®city.
277H mutations have not been observed in tumours. 277Y mutations have been seen, but we chose not to include 277Y in the mutagenesis primer used for the screen because Txx codons can encode the wild type residue, cysteine. Given the ®nding that 277H can activate transcription from a TTT site, and the fact that 277Y can be accommodated in the modi®ed structure (data not shown), we chose to examine speci®cally 277Y mutants for activation from TTT sites. These experiments clearly showed the advantage of combining the 120H and 121G mutations with codon 277 changes for activation from TTT sites, since the single 277Y mutant could only activate from 46TTT sites in yeast, whereas the triple mutant activates from 26TTT sites.
One important dierence between the 277H/Y mutants and wild type p53 is that the former should not trigger feedback regulation by MDM2 (Haupt et al., 1997; Kubbutat et al., 1997) . This feedback loop will tend to limit the bene®cial eects of wild type p53 in tumour cells. Although endogenous wild type p53-induced MDM2 activation in normal cells transduced by a virus expressing the 277H/Y mutants can limit both the level and activity of the exogenous p53, this regulation should be absent in p53-de®cient tumour cells, where the 277H/Y mutants would be expected to show signi®cantly more activity than a comparable wild type transgene.
The use of adenoviruses to express wild type p53 for cancer gene therapy is now entering clinical practice, although situations where such therapy has decisive advantages have yet to be clearly de®ned. Use of wild type p53 carries the risk that some normal cells may be killed, particularly if high level p53 expression bypasses normal regulatory controls. Use of p53 mutants to activate transcription of conditionally toxic genes, for example the Herpes simplex thymidine kinase gene (Culver et al., 1992; Ezzeddine et al., 1991) , would allow tumour-targeting by p53, which acts as a sensor for the malignant state, but place control over cell killing in the hands of the clinician. We have shown here that it is possible in principle to target cells with p53 speci®city mutants in this way, whether by cotransduction of exogenous p53 mutants and responsive transcription reporters into any p53-mutant cell, or by transduction of the latter alone into cells expressing endogenous p53 speci®city mutants. (Kovar et al., 1993) were transfected with 3 mg luciferase reporters by lipofection. To test the DNA damage response, cells were irradiated with 6 Gy X-rays (Phillips RT 100) 44 h after transfection and collected for luciferase assays after a further 24 h incubation p53 specificity mutants J Gagnebin et al
